Radiotherapy and Anti-PD-1 in Low-risk ES-ENKTCL

NCT05149170 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

30

Enrollment

OTHER

Sponsor class

Conditions

Early-stage
Extranodal NK-T-Cell Lymphoma, Nasal and Nasal-Type

Interventions

DRUG: Anti-PD-1 monoclonal antibody

Sponsor

Chinese Academy of Medical Sciences

Collaborators

[object Object]
[object Object]
[object Object]